Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
for Prostate Cancer
Drug: JANX007
1 location in Nashville
Sponsor: Janux Therapeutics
Sex: Male·Age: 18+
Code: NCT07813637·Phase 1·Recruiting·Listed Sep 10, 2026
Men's health Clinical Trials in Nashville, TN
As of September 2026, 35 paid clinical trials are recruiting for Men's health in Nashville, Tennessee. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Filter results
Newly added in Nashville
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
36 clinical trials for Men's health
·Clear filters· Email me when a new men's health trial opens in Nashville, TN.
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
for Metastatic Castration-resistant Prostate Cancer
Sites in Nashville +44 more locations
Sponsor: Amgen
Sex: Male·Age: 18+
Code: NCT07213674·Phase 3·Recruiting·Listed Oct 2025
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
for Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Drug: Mevrometostat
Sites in Nashville, Hendersonville +122 more locations
Sponsor: Pfizer
Sex: Male·Age: 18+
Code: NCT07028853·Phase 3·Recruiting·Listed Jun 2025
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
for Prostate Cancer
Sites in Nashville, Memphis +48 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: Male·Age: 18+
Code: NCT06925737·Phase 3·Recruiting·Listed Apr 2025
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
for Prostate Cancer
Sites in Nashville +20 more locations
Sponsor: Amgen
Sex: Male·Age: 18+
Code: NCT04221542·Phase 1·Recruiting·Listed Jan 2020
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
for Advanced Solid Tumor
Sites in Nashville +30 more locations
Sponsor: PMV Pharmaceuticals, Inc
Sex: All·Age: 12+
Code: NCT04585750·Phase 1, Phase 2·Recruiting·Listed Oct 2020
FOG-001 in Locally Advanced or Metastatic Solid Tumors
for Cancer
Sites in Nashville +29 more locations
Sponsor: Parabilis Medicines, Inc.
Sex: All·Age: 18+
Code: NCT05919264·Phase 1, Phase 2·Recruiting·Listed Jun 2023
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
for Prostate Cancer
Drug: JANX007
Sites in Nashville +32 more locations
Sponsor: Janux Therapeutics
Sex: Male·Age: 18 - 100
Code: NCT05519449·Phase 1·Recruiting·Listed Aug 2022
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
for Prostate Cancer
Sites in Nashville +28 more locations
Sponsor: Clarity Pharmaceuticals Ltd
Sex: Male·Age: 18+
Code: NCT06056830·Phase 3·Recruiting·Listed Sep 2023
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
for Metastatic Solid Tumor
Drug: LY4052031
Sites in Nashville +20 more locations
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT06465069·Phase 1·Recruiting·Listed Jun 2024
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
for Non Small Cell Lung Cancer
Sites in Nashville +21 more locations
Sponsor: SystImmune Inc.
Sex: All·Age: 18+
Code: NCT05983432·Phase 1·Recruiting·Listed Aug 2023
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
for Advanced Solid Tumor
Sites in Nashville +11 more locations
Sponsor: Daiichi Sankyo
Sex: All·Age: 18+
Code: NCT06172478·Phase 2·Recruiting·Listed Dec 2023
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
for Metastatic Prostate Cancer
Sites in Nashville +16 more locations
Sponsor: Janssen Research & Development, LLC
Sex: Male·Age: 18+
Code: NCT06800313·Phase 1, Phase 2·Recruiting·Listed Jan 2025
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
for Metastatic Castration-Resistant Prostate Cancer
Sites in Nashville +22 more locations
Sponsor: Kyntra Bio
Sex: Male·Age: 18+
Code: NCT06842498·Phase 2·Recruiting·Listed Feb 2025
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
for Prostate Cancer
Sites in Nashville +11 more locations
Sponsor: Astellas Pharma Global Development, Inc.
Sex: Male·Age: 18+
Code: NCT07005154·Phase 2·Recruiting·Listed Jun 2025
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
for Metastatic Castration-Resistant Prostate Cancer
Sites in Nashville +13 more locations
Sponsor: Zenith Epigenetics
Sex: Male·Age: 18+
Code: NCT04986423·Phase 2·Recruiting·Listed Aug 2021
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
for Prostate Cancer
Sites in Nashville +13 more locations
Sponsor: Astellas Pharma Global Development, Inc.
Sex: Male·Age: 18+
Code: NCT04729114·Phase 1·Recruiting·Listed Jan 2021
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
for Advanced Solid Tumor
Sites in Nashville +20 more locations
Sponsor: Clasp Therapeutics, Inc.
Sex: All·Age: 18+
Code: NCT06778863·Phase 1·Recruiting·Listed Jan 2025
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
for Brain Cancer
Sites in Nashville, Memphis +14 more locations
Sponsor: Adela, Inc
Sex: All·Age: 40+·Accepts healthy volunteers
Code: NCT05366881·Recruiting·Listed May 2022
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
for Advanced Prostate Cancer
Sites in Nashville +1 more location
Sponsor: Genentech, Inc.
Sex: Male·Age: 18+
Code: NCT07567846·Phase 1, Phase 2·Recruiting·Listed May 2026
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
for Metastatic Castration-resistant Prostate Cancer
Sites in Nashville +16 more locations
Sponsor: BioNTech SE
Sex: Male·Age: 18+
Code: NCT07365995·Phase 3·Recruiting·Listed Jan 2026
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
for Advanced HR+/HER2- Breast Cancer
Drug: GVV858
Sites in Nashville +2 more locations
Sponsor: Novartis Pharmaceuticals
Sex: All·Age: 18+
Code: NCT07288359·Phase 1, Phase 2·Recruiting·Listed Dec 2025
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
for Cancer
Sites in Nashville +6 more locations
Sponsor: Angiex, Inc.
Sex: All·Age: 18+
Code: NCT06440005·Phase 1·Recruiting·Listed Jun 2024
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
for Biliary Tract Cancer
Sites in Nashville +5 more locations
Sponsor: ModeX Therapeutics, An OPKO Health Company
Sex: All·Age: 18+
Code: NCT06239194·Phase 1, Phase 2·Recruiting·Listed Feb 2024
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
for Lung Cancer (NSCLC)
Sites in Nashville +2 more locations
Sponsor: Phrontline Biopharma
Sex: All·Age: 18+
Code: NCT07181473·Phase 1·Recruiting·Listed Sep 2025
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
for Advanced Malignant Neoplasm
Sites in Nashville +3 more locations
Sponsor: AtlasMedx, Incorporated
Sex: All·Age: 18+
Code: NCT04503265·Phase 1, Phase 2·Recruiting·Listed Aug 2020
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
for Metastatic Prostate Cancer
Sites in Nashville, Memphis +15 more locations
Sponsor: VA Office of Research and Development
Sex: Male·Age: 18+
Code: NCT05011383·Phase 2·Recruiting·Listed Aug 2021
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
for Castration-Resistant Prostate Cancer (CRPC)
Drug: Apalutamide
Sites in Nashville +13 more locations
Sponsor: Monte Rosa Therapeutics, Inc
Sex: Male·Age: 18+
Code: NCT07745361·Phase 2·Recruiting·Listed Aug 2026
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
for Metastatic Castration-resistant Prostate Cancer
Sites in Nashville +24 more locations
Sponsor: AstraZeneca
Sex: Male·Age: 18+
Code: NCT07611110·Phase 3·Recruiting·Listed May 2026
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
for Prostate Cancer
Sites in Nashville +5 more locations
Sponsor: Janux Therapeutics
Sex: Male·Age: 18+
Code: NCT07545811·Phase 1·Recruiting·Listed Apr 2026
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
for Prostate Cancer
Sites in Nashville +7 more locations
Sponsor: AstraZeneca
Sex: Male·Age: 18+
Code: NCT07336446·Phase 1, Phase 2·Recruiting·Listed Jan 2026
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
for Endometrial Cancer
Sites in Nashville +10 more locations
Sponsor: AstraZeneca
Sex: All·Age: 18 - 130
Code: NCT05489211·Phase 2·Recruiting·Listed Aug 2022
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
for Prostate Cancer
Drug: Saruparib
Sites in Nashville +36 more locations
Sponsor: AstraZeneca
Sex: Male·Age: 18+
Code: NCT06952803·Phase 3·Recruiting·Listed May 2025
DESTINY-PANTUMOUR04
for Adenocarcinoma (NOS)
Sites in Nashville +17 more locations
Sponsor: AstraZeneca
Sex: All·Age: 18 - 130
Code: NCT07124000·Recruiting·Listed Aug 2025
PSMA PET Combined With MRI for the Detection of PCa
for PCA
Sites in Nashville, Germantown +14 more locations
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
Sex: Male·Age: 18+·Accepts healthy volunteers
Code: NCT07052214·Phase 3·Recruiting·Listed Jul 2025
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
for Advanced Solid Tumor
Sites in Nashville +7 more locations
Sponsor: MOMA Therapeutics
Sex: All·Age: 18+
Code: NCT06545942·Phase 1·Recruiting·Listed Aug 2024
Top Research Study Locations in Nashville
Researchers run research studies in Nashville, TN at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Vanderbilt University Medical Center | Colorectal Cancer, Critical Illness, Parkinson Disease | 374 |
| SCRI Oncology Partners | Breast Cancer, Colorectal Cancer, Advanced Solid Tumor | 125 |
| Vanderbilt University/Ingram Cancer Center | Stage IV Colorectal Cancer AJCC v8, Head and Neck Squamous Cell Carcinoma, Malignant Solid Neoplasm | 81 |
| Sarah Cannon Research Institute | Advanced Solid Tumor, Prostate Cancer, Advanced Solid Tumors | 63 |
| Vanderbilt University | Autoimmune Diseases, Breast Cancer, Cardiac Failure | 53 |
| Tennessee Oncology | Multiple Myeloma, Breast Cancer, Carcinoma, Non-Small-Cell Lung | 50 |
| Vanderbilt-Ingram Cancer Center | Breast Cancer, Colorectal Cancer, Endometrial Cancer | 36 |
| The Children's Hospital at TriStar Centennial | Malignant Solid Neoplasm, Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia | 26 |
| Monroe Carell Jr. Children's Hospital at Vanderbilt | Acute Kidney Injury, Acute Myeloid Leukemia, Angelman Syndrome | 13 |
| Tennessee Oncology, PLLC | Advanced Solid Tumor, Breast Cancer, Advanced Breast Cancer | 13 |
| TriStar Centennial Medical Center | Coronary Artery Disease, Acute Lower Limb Arterial Occlusion, Acute Myeloid Leukemia (AML) | 13 |
| Vanderbilt Breast Center at One Hundred Oaks | Metastatic Malignant Solid Neoplasm, Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | 13 |
| Sarah Cannon Research Institute Oncology Partners | Advanced Cancer, Advanced NRAS-Mutant Melanoma, Advanced NRAS-Mutant Solid Tumors | 10 |
| Tennessee Valley Healthcare System Nashville Campus, Nashville, TN | Cardiovascular Disease, Acute Kidney Injury (AKI), Aging | 10 |
| Ascension Saint Thomas | Coronary Artery Disease, Mitral Regurgitation, Acute or Chronic Coronary Artery Disease | 9 |
| GSK Investigational Site | Neoplasms, Multiple Myeloma, Irritable Bowel Syndrome | 9 |
| Henry-Joyce Cancer Clinic | Colorectal Neoplasms, Advanced Renal Cell Carcinoma, Advanced or Metastatic Renal Cell Carcinoma | 8 |
| Vanderbilt Eye Institute | Geographic Atrophy (GA), Macular Edema Secondary to Inflammation, Age - Related Macular Degeneration (AMD) | 8 |
| Meharry Medical College | ARDS, Cardiovascular Diseases, Cognitive Impairment, Mild | 7 |
| Tennessee Retina, PC | Neovascular Age-Related Macular Degeneration (nAMD), Age-related Macular Degeneration (AMD), Choroidal Melanoma | 7 |
| Vanderbilt Medical Center | Acinar Cell Carcinoma, Advanced Cancer, Alzheimer Disease | 7 |
| Autonomic Dysfunction Center/ Vanderbilt University Medical Center | Autonomic Failure, Multiple System Atrophy, Pure Autonomic Failure | 6 |
| Centennial Medical Center | Cardiovascular Diseases, Coronary Artery Disease, Heart Failure | 6 |
| Sarah Cannon Research Institute (SCRI) Oncology Partners | Advanced Solid Tumor, Metastatic Solid Tumor, Ovarian Cancer | 6 |
| Tennessee Oncology, PLLC - Investigational Drug Services | Advanced/Metastatic Urothelial Cancer, Cancer of the Prostate, Hormone Sensitive Prostate Cancer | 6 |
Active & Upcoming Studies in Nashville (2026)
Recruiting trials in Nashville grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (553 active studies)
- Pilot Study of Casdatifan-Treated Refractory Renal Cell Carcinoma · EARLY_Phase 1 · Vanderbilt-Ingram Cancer Center
- PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC · Phase 2 · Vanderbilt-Ingram Cancer Center
Cardiovascular (91 active studies)
Neurology & pain (63 active studies)
- Cholinergic Deep Brain Stimulation for Alzheimer's Disease · Vanderbilt University Medical Center
- Alzheimer's Tau Platform: Regimen A - AADvac1 · Phase 2 · Paul S. Aisen
Diabetes & metabolic (50 active studies)
- HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide · Phase 2 · Vanderbilt University Medical Center
- Transition to Ambulatory Bariatric Surgery (TABS) Trial · Vanderbilt University Medical Center
Eye & vision (18 active studies)
- A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration · Phase 3 · Amgen
- A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated · Phase 1, Phase 2 · Boehringer Ingelheim
Mental health & behavior (15 active studies)
- Cognitive Enhancement in Recurrent Depression (The COG-D-R Study) · Vanderbilt University Medical Center
- GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · Vanderbilt University Medical Center
HIV / STI (8 active studies)
- Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults · Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID)
- GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · Vanderbilt University Medical Center
Vaccines (7 active studies)
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age · Phase 3 · GlaxoSmithKline
- Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS · Phase 2 · Vanderbilt University Medical Center
Pediatric (7 active studies)
- Neonatal Platelet Transfusion Threshold Trial · NICHD Neonatal Research Network
- Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment · Fresenius Kabi
Common conditions studied in Nashville
- Breast Cancer (40 active studies)
- Colorectal Cancer (33 active studies)
- Advanced Solid Tumor (30 active studies)
- Ovarian Cancer (29 active studies)
- Prostate Cancer (25 active studies)
- Endometrial Cancer (23 active studies)
Leading research sponsors in Nashville
- Vanderbilt University Medical Center
- AstraZeneca
- Vanderbilt-Ingram Cancer Center
- National Cancer Institute (NCI)
- Eli Lilly and Company
Frequently asked questions
How many paid clinical trials are currently recruiting in Nashville?
There are approximately 1,346 recruiting clinical trials in Nashville, Tennessee listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Nashville pay participants?
Most recruiting trials in Nashville compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Nashville?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Nashville?
The most common conditions under active study in Nashville include Breast Cancer (40), Colorectal Cancer (33), Advanced Solid Tumor (30), Ovarian Cancer (29), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Nashville?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Nashville on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Nashville?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Nashville?
Recruiting research sites in Nashville include Vanderbilt University Medical Center, SCRI Oncology Partners, Vanderbilt University/Ingram Cancer Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Nashville right now?
The largest active categories in Nashville are Cancer & tumors (553), Cardiovascular (91), Neurology & pain (63). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
Browse more clinical trials
Other cities in Tennessee
Memphis, TN(453)Knoxville, TN(217)Chattanooga, TN(126)Germantown, TN(96)Jackson, TN(44)Collierville, TN(43)Franklin, TN(32)Kingsport, TN(31)Cordova, TN(30)Murfreesboro, TN(24)Johnson City, TN(22)Smyrna, TN(14)Tullahoma, TN(14)Hermitage, TN(9)Mount Juliet, TN(8)Oak Ridge, TN(8)Brentwood, TN(7)Bristol, TN(7)Clarksville, TN(7)Cleveland, TN(7)Hendersonville, TN(7)Shelbyville, TN(7)Bartlett, TN(6)Lebanon, TN(6)Cookeville, TN(5)Crossville, TN(5)Gallatin, TN(5)Hixson, TN(5)Jefferson City, TN(5)Powell, TN(5)Dickson, TN(4)Greeneville, TN(4)Morristown, TN(4)Columbia, TN(3)Mountain Home, TN(3)Nashvile, TN(3)Goodlettsville, TN(2)Maryville, TN(2)Tennessee City, TN(2)Winchester, TN(2)Alcoa, TN(1)Harriman, TN(1)Lenoir City, TN(1)Mephis, TN(1)Nasville, TN(1)Sevierville, TN(1)Spring Hill, TN(1)